Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;5(6):511-6.
doi: 10.1097/COH.0b013e32833ed7ec.

Biomarkers and HIV-associated cardiovascular disease

Jason V Baker  1 , Daniel Duprez
Affiliations
Review

Biomarkers and HIV-associated cardiovascular disease

Jason V Baker et al. Curr Opin HIV AIDS. 2010 Nov.

Abstract

Purpose of review: Our goal is to summarize recent literature on biomarkers of cardiovascular disease (CVD) in the setting of HIV infection with an emphasis on those associated with clinical events.

Recent findings: Epidemiological data have demonstrated that HIV infection is associated with increases in well established markers of inflammation and thrombosis, and levels of high sensitivity C-reactive protein, interleukin-6, and D-dimer predict CVD and mortality risk in HIV cohorts. Levels of interleukin-6, D-dimer and endothelial adhesion molecules increase when antiretroviral therapy is interrupted, suggesting that HIV replication may be driving CVD risk in this context. However, data on changes in many CVD biomarkers after starting antiretroviral therapy are inconsistent or lacking. Finally, high-density lipoprotein particles may be more informative than other lipoprotein measures for CVD risk specifically among individuals with HIV infection.

Summary: Biomarkers of inflammation and thrombosis have the potential to improve CVD risk stratification beyond traditional and HIV-specific factors, and may prove useful for evaluating CVD prevention strategies for individuals with HIV infection.

PubMed Disclaimer

References

    1. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198–210. - PMC - PubMed
    1. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41(2):194–200. - PubMed
    1. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections; 2009 February 8–11th; Montreal, CA. (abstract #707).
    1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–2296. - PubMed
    1. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735. - PubMed

Publication types

MeSH terms